Clarient Inc.

RON A. ANDREWS has been Chief Executive Officer since July 2004. From August 2002, Andrews was Senior Vice President Global Marketing and Commercial Business Development at Pleasanton, CA-based Roche Molecular Diagnostics. In that role, he developed and led the strategic execution for all diagnostic commercial operations. This included the oversight of five Business Sector Vice Presidents responsible for all aspects of global marketing and business development in the areas of blood screening, virology, women’s health, microbiology and automation/emerging diagnostics. Ron was also responsible for executive direction of all marketing functions, directed the development of the 10-year Strategic Plan for the organization, and completed the reorganization of commercial operations during that period. From 2000 to 2002, Ron held two senior executive positions with Indianapolis-based Roche Diagnostics Corporation. As Vice President, U.S. Commercial Operations, Molecular Diagnostics, he directed sales, marketing, technical field support, and product development activities and was responsible for US commercial strategy development for the clinical laboratory market. Prior to that, as Vice President, Marketing, US Commercial Operations, he was responsible for planning and directing all aspects of the Roche US Laboratory Systems Commercial Operations Marketing which included the clinical chemistry, immunochemistry, hematology, near patient testing and molecular markets. From 1995 to 2000, Ron was Vice President of Atlanta-based Immucor, Inc. where he helped lead the transition of that company from a reagent manufacturer to an instrument systems company. Prior to Immucor, he spent almost 10 years in management positions of increasing responsibility at Chicago- based Abbott Diagnostics, culminating in the position of Senior Marketing Manager, Business Unit Operations. Ron earned a Bachelor’s degree in Biology and Chemistry from Spartanburg, SC-based Wofford College in 1981 and has participated extensively in the executive development programs at both Roche and Abbott Labs. He currently lives with his wife and three children in Coto de Caza, CA. Print

Michael J. Pellini, M.D. joined Clarient, Inc. as Chief Operating Officer from Safeguard Scientifics, Inc. in September 2007, and became President and COO of Clarient in April 2008. Mike draws upon years of experience in life sciences and laboratory executive management to support Clarient’s operations as the company continues its rapid growth and market expansion. As a member of Safeguard’s Life Sciences team, Mike leveraged his business and medical expertise to explore new market opportunities, evaluate growth potential of prospects and provide support to Safeguard and its partner companies. Prior to joining Safeguard, Mike was EVP and Chief Operating Officer at Lakewood Pathology Associates, Inc., a national anatomical pathology company that provides comprehensive molecular and pathology services, which was acquired by Water Street Health Partners in 2006. Prior to that, Mike was an Entrepreneur in Residence at BioAdvance, where he was responsible for reviewing and evaluating early stage life science companies. From 1999 to 2004, Mike served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004. Mike is a native of the greater Philadelphia region. He trained as a primary care physician in the Thomas Jefferson University Health System. Before attending medical school, he worked in the investment banking industry in both Philadelphia and Sydney, Australia. Mike received his MBA from Drexel University and has a Bachelor’s degree from Boston College. Education BA, Boston College MBA, Drexel University MD, Jefferson Medical College of Thomas Jefferson University Previous Experience Safeguard Scientifics, Inc. - Vice President, Life Sciences Lakewood Pathology Associates, Inc. – Executive Vice President / Chief Operating Officer BioAdvance – Entrepreneur in Residence Genomics Collaborative, Inc. – President and CEO Current Boards Coriell Institute of Medical Research – Executive Committee of the Board of Trustees Jefferson Medical College – Alumni Association Executive Committee Boston College – Technology Council Journal of Biotechnology Healthcare – Editorial Board Print

Kenneth J. Bloom, MD has been Medical Director since August 2004 and Chief Medical Officer since 2005. Dr. Bloom came to Clarient from Irvine, CA-based US Labs, where he served as Senior Medical Director since 2002. Prior to that, Dr. Bloom spent more than two decades serving in senior academic, consultative and clinical roles with leading hospitals and healthcare enterprises principally in the specialization of cancer care. Dr. Bloom’s academic posts have included over 10 years as Associate Professor of Pathology at Chicago-based Rush Medical College, as well as one year as a visiting Professor in the Department of Computer Science at DePaul University. Over the past 15 years, Dr. Bloom has held more than 10 appointed positions at Chicago-based Rush Presbyterian - St. Luke’s Medical Center, one of the leading cancer research hospitals in the US. Those positions included Director of Laboratory Operations, Director of Immunohistochemistry, and Director of the Breast Service in the Department of Pathology, Consultant to the Rush Breast Cancer Center, and Director of Information Services for the Rush Cancer Institute. Dr. Bloom has, for more than three decades, been a prolific researcher and lecturer in the fields of pathology and, specifically, cancer related topics. During his tenure at Rush, his published studies validating the benefits of ACIS® (Automated Cellular Imaging System) image analysis for HER2 evaluation were instrumental in gaining broad acceptance for the Clarient technology. He has been a member of the College of American Pathologists since 1987 and currently serves as a member of the Immunohistochemistry and Technology Assessment Committees for that organization. In addition to US LABS and the other roles mentioned above, Dr. Bloom has served the industry off and on for the past 20 years in both advisory and operational roles. Those appointments include Board of Directors seats, consulting roles and executive posts including executive level positions at both diagnostics technology and information technology firms.

Raymond J. Land, has been Senior Vice President & Chief Financial Officer since June 2008 and Corporate Secretary since July 2008. Ray has more than 30 years of financial experience and has had responsibility for accounting, tax, treasury, facilities, investor relations, information management, strategic planning and business development over those years. Prior to joining us, Ray served as Senior Vice President and Chief Financial Officer with Safeguard Scientifics, Inc. (NYSE: SFE), a company that provides growth capital to life science and technology companies. Previously, Ray was an Executive Vice President and Chief Financial Officer with Medcenter Solutions, Inc., a global pharmaceutical marketing company that specializes in providing online solutions for physicians, patients and sales representatives. Ray was also the Senior Vice President and Chief Financial Officer of Orchid Bioscience (Nasdaq: ORCH), a DNA laboratory testing service company in 2005 and 2006. From 1997 to 2005, Ray was Vice President and Chief Financial Officer for Genencor International, Inc., a global biotechnology company that went public (Nasdaq: GCOR) during his tenure and was valued at $1.2 billion when it was sold in 2005. Ray’s experience also includes serving, from 1991 to 1996, as Senior Vice President and Chief Financial Officer of West Pharmaceutical Services, Inc (NYSE: WST), a global manufacturer of pharmaceutical packaging and drug delivery products. For the nine years prior, Ray held a number of positions with Campbell Soup Company (NYSE: CPB) including Vice President – Corporate Controller and Vice President – General Manager. Prior to that Ray was an audit manager with Coopers & Lybrand Ray has relocated to Southern California with his wife. He received a BBA in Accounting and Finance from Temple University

David J. Daly has been Vice President of Sales since February, 2005. In 2006, Dave took over responsibility for Marketing in addition to Sales. And in 2007, Dave added all Commercial Operations to his responsibilities. Prior to joining Clarient, Dave served as Area Marketing Manager for Roche Diagnostics, where he was responsible for the establishment of Molecular Centers of Excellence throughout the western region. Prior to Roche, Dave spent ten years with Abbott Laboratories, Diagnostic Division. He started his career as a territory sales representative and took on increasing levels of responsibility throughout his tenure. His roles included Worldwide Marketing, where he was responsible for the development and implementation of Abbott’s Global lab automation strategy and Sales Management where he served as District Manager for Hematology products. Dave finished his career at Abbott as Director of US Sales, Animal Health division, where he was responsible for a $50 million annual sales plan and managed a 35 member sales organizations. Mr. Daly earned a Master’s Degree in Economics from the University of California, Santa Barbara and graduated cum laude with a Bachelor’s Degree in Economics from the University of California, Irvine.

Since 2003, Dr. Scher has been Vice President, Global Clinical R&D of Merck KGaA Darmstadt, Germany, an international division of Merck, a global pharmaceutical products and services company. From 1999 to 2002, Dr. Scher was a full time business consultant to the chief executive officer of Merck KGaA. From 1992 until 1999, Dr. Scher served as Vice President and Senior Vice President, Drug Development and Medical Affairs at Merck, Astra Merck and Astra Zeneca. Dr. Scher has authored 98 peer reviewed publications, 39 book chapters and edited two books. He received a B.S. in chemistry from the New York State University at Albany and an M.D. from the Albert Einstein College of Medicine. He is board certified in internal medicine and rheumatology.

Ainura Kyshtoobayeva, M.D., Ph.D. is in charge of IHC quality control including validation of new IHC tests and technical support for pathologists. She brings 20 years of experience with expertise in IHC, histology, and FISH. Previously she served as a Research Pathologist at Oncotech where she also served as Manager of Histology and IHC. Recently, she served as Director of IHC for US Labs. Dr. Kyshtoobayeva is a research pathologist from St. Petersburg, Russia. She received her Medical Degree from the Prof. N.N. Petrov Research Institute of Oncology of the USSR Ministry of Public Health. She was awarded her Ph.D. in Pathology from the Board of the Leningrad State Institute of Continuing Education. She returned to the Petrov Research Institute to serve as a pathologist and Senior Research Scientist. She completed her fellowship at the Oncology Research Faculty Development Program at the National Institutes of Health, Bethesda, Maryland. Dr. Kyshtoobayeva has published extensively in the areas of breast, prostate, and colon cancer. * Dr. Kyshtoobayeva is not licensed in California and is not providing patient services in California

Alan Wells is responsible for logistics, client services, and accessioning at Clarient. He brings to Clarient over 25 years of laboratory operations and management experience. Previously, he was Director of Operations and Purchasing at Oncogenetics Laboratories from its inception as a start-up, where he was responsible for establishing and building all operational functions in addition to human resources, billing and collections, facilities management and warehousing. IMPATH purchased Oncogenetics, and he continued in his role as Director of Operations for the Phoenix facility until joining Clarient in 2004. Prior to 1992, Alan held a variety of operations and administrative management roles at Genetrix, MetPath/MetWest, Central Diagnostic Laboratory and Automated Pathology Laboratory.

Dr. Hii is a practicing Pathologist and Board Certified in Anatomic and Clinical Pathology as well as Hematology. He received his Medical Degree as well as residency training at Loma Linda University. Dr. Hii completed his surgical pathology fellowship at the Los Angeles County - University of Southern California Medical Center and a fellowship in Hematopathology at Cedars-Sinai Medical Center in Los Angeles. He has previously served as Associate Medical Director at US Labs. Dr. Hii currently is the California Tumor Tissue Registry Co-Director for Web and Multimedia Development. He is a member of the College of American Pathologists, American Society for Clinical Pathology, and American Society of Hematology.

Claudia Bunting oversees the administrative aspects of the histology, imaging, immunohistochemistry, flow cytometry and molecular departments of Clarient. She brings over 30 years of experience in anatomical pathology, with approximately 17 years served in commercial laboratories. She served as Supervisor and then Manager of the Anatomical Department at Ameripath for 14 years and was responsible for developing a fast growing IHC department. In addition, she was the Anatomical Pathology Director at US Labs where she successfully expanded a highly technical IHC laboratory and flow cytometry laboratory. She received her histology training at Hurley Hospital in Flint, Michigan.

Dr. Hibbard completed her postdoctoral research in the Department of Pathology at Brigham and Women’s Hospital in Boston and her thesis research in the Department of Microbiology and Molecular Genetics at UC Irvine. Dr. Hibbard has a bachelor’s degree in biology from UC San Diego and a Ph.D. in biological sciences from UC Irvine. She earned a certificate from the American Board of Medical Genetics in Clinical Molecular Genetics and Clinical Cytogenetics after training at Harvard Medical School. She is also a licensed Clinical Genetic Molecular Biologist and Clinical Cytogeneticist by the State of California Department of Health Services. Prior to joining Clarient, Dr. Hibbard spent six years as Director of Genetics at Irvine-based US Labs, where she helped launch and direct the operations of the genetics program. She was responsible for the technical operations, including policy review, new procedure validation and case review/sign out, of the cytogenetic, FISH and molecular genetic laboratories. Prior to her work at US Labs, Dr. Hibbard spent a year as Director of Cytogenetics at IMPATH, Inc, where she started up their New York cytogenetic operation. Dr. Hibbard began her career in genetics as a cytogenetic technologist, working at San Juan Capistrano, CA-based Nichols Institute.

Dr. Chen is board certified in the areas of Anatomic and Clinical Pathology as well as Hematology. He contributes over 20 years experience in medical research and numerous publications in the field to his credit. Dr. Chen came to Clarient after having been the Director of Hematopathology and Flow Cytometry at US Labs since December 2002. Most recently, he served as Interim Medical Director at the same institution. He received a medical degree from Taipei Medical College, Taipei, Taiwan and completed his residency training in pathology at Temple University School of Medicine, Philadelphia, Pennsylvania. Dr. Chen received a Ph.D. in Molecular and Cellular Pathology from Temple University before moving to neighboring Thomas Jefferson University, Philadelphia, Pennsylvania, where he served as the Associate Director of the Molecular Diagnostic Division and Assistant Professor of Pathology. He completed a fellowship in Hematopathology at the University of Maryland, Baltimore, MD, where he also served as Assistant Professor in the Pathology Department. In 2000 he served as a fellow in Immunohistochemistry in the National Institutes of Health. Dr. Chen joined Quest Diagnostics at Nichols Institute in 2001 as a staff pathologist. His research interests include normal and abnormal cell proliferation. His expertise is in molecular biolo

Dr. Smith provides consulting and management services to the healthcare industry and to venture capital firms. Dr. Smith has over 25 years of experience in healthcare management, outreach laboratory, pathology, laboratory medicine, and blood banking. He is a board-certified clinical and anatomic pathologist and transfusion medicine specialist. From 1997 to 2005, Dr. Smith served on the executive management team and Board of Directors of AmeriPath, Inc., a provider of diagnostic laboratory services. While at AmeriPath, Dr. Smith served as Senior Vice President and Medical Director from 1997 to 2001, Chief Medical Officer from 2001 to 2003 and Executive Director of AmeriPath s Center for Advanced Diagnostics from 2003 to 2005. In addition, Dr. Smith served on AmeriPath Inc. s Board of Directors from 2001 to 2003 and as the Executive Vice President of Genomic Strategies with AmeriPath from 2001 to 2005.

Ann Huntress Lamont has been with Oak Investment Partners since 1982 and became a General Partner in 1986. Ann focuses on healthcare and financial information technology and services. Ann's more recent investments include American Esoterics, United BioSource, Athenahealth, Patient Care, Psychiatric Solutions and Vesta. Prior services investments include Odyssey Healthcare, Pacific Dental Benefits, Radiant Research and Oaktree/Oxford Health. Earlier in Ann's venture career, she developed a number of successful information technology and biopharmaceutical investments. Prior to joining Oak, Ann was a research associate with Hambrecht & Quist, and received her BA in Political Science from Stanford University.

Mr. Slattery has served as President of Quintus Corporation, an originator of new companies utilizing science from several universities, since June 1994. Prior to June 1994, Mr. Slattery served as a Director, President and Chief Executive Officer of LFC Financial Corporation, a diversified financial corporation. Mr. Slattery is a trustee of the Jefferson Health System and The Franklin Institute and the Chairman of the Board of the Main Line Health Systems. In addition, in connection with his service as President of Quintus Corporation, Mr. Slattery is a director of numerous private companies, primarily engaged in technology ventures. Mr. Slattery received an A.B. degree from Princeton University and a J.D. degree from the University of Pennsylvania Law School.

Mr. Hamm was a Partner of PricewaterhouseCoopers until his retirement in 2004, serving most recently as National Partner-in-Charge of PricewaterhouseCoopers Middle Market Practice and as a member of the firm s Audit Leadership Team. In 1985 Mr. Hamm was President of a venture backed computer software company and a member of the Board of Directors of Community Bank. From 1980 to 1985, Mr. Hamm was a Partner at Peat Marwick Mitchell. Mr. Hamm is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from San Diego State University.

As Executive Vice President and Managing Director of Life Sciences, Jim applies his broad industry knowledge to drive Safeguard’s partnership opportunities in Life Sciences. His significant experience as a marketing / sales and business development executive for leading pharmaceutical, medical device, diagnostics and software companies spans more than 20 years and covers assignments throughout the United States, Europe and Asia. Prior to joining Safeguard, Jim was Chief Executive Officer of TouchPoint Solutions, Inc., a provider of software that enables customers to develop and deploy applications, content and media on multi-user interactive devices. Prior to TouchPoint, Jim served as Group President of Dendrite International, a provider of sales, marketing, clinical and compliance solution services to global pharmaceutical and other life sciences companies. In his tenure as Group Director of Corporate Business Strategy and Planning at GlaxoSmithKline, he served on the Global Predictive Medicine Board of Directors, evaluating acquisition and alliance opportunities, reengineering projects and facilitating change management teams. His experience also includes executive international assignments setting up international businesses and identifying strategic growth opportunities for Merck KGaA and Baxter. As Chief Executive Officer at publicly traded Isuta Group, Jim redesigned the company’s value proposition and led a profitable expansion throughout Asia and enabled the company’s survival of the Asian economic crisis. These initiatives positioned the group to become a world leader in all major product groups. Jim and his team actively oversee Safeguard’s life sciences partner companies and continuously evaluate new growth opportunities in life sciences companies. Jim believes that by providing capital, as well as a range of strategic, operational and management resources, Safeguard is uniquely positioned to build value in growth-stage life sciences companies. Jim has completed more than 20 acquisitions, mergers and divestitures in his 20 plus years of experience, and seeks opportunities to partner with innovative entrepreneurs within diagnostics, medical devices and specialty pharmaceuticals. EXPERIENCE * TouchPoint Solutions, Inc. - CEO * Dendrite International - Group President * GlaxoSmithKline - Group Director, Corporate Business Strategy and Planning * Isuta Holdings - CEO * Baxter/Merck KGaA - Director, International Business BOARD MEMBER Safeguard Partner Companies * Cellumen, Inc. * Clarient, Inc. (Nasdaq: CLRT) * Molecular Biometrics, Inc. * Rubicor Medical, Inc. EDUCATION * BBA, Marshall University * MBA, University of New Haven

As President and Chief Executive Officer of Safeguard, Peter J. Boni draws on more than 25 years of experience as the CEO of technology companies in all stages of growth, and as an operating partner with a large global private equity firm. With both the deal savvy and operating expertise that a successful career affords, Peter is responsible for developing and executing Safeguard’s corporate strategy. His goal is to build on the company’s legacy of identifying businesses in the Technology and Life Sciences sectors with superior growth potential, and applying Safeguard’s capital and strategic, operational and management resources to enhance long-term value for shareholders, partner companies and employees. Peter is recognized as a leader in both building businesses and restoring troubled companies to growth and profitability. In addition to acting as CEO for several publicly-traded and privately-held companies, he has served as a chairman, a Fortune 500 corporate executive, a NYSE Fortune 1000 president, a management consultant, board member, investor and advisor to institutional investors in both early- and later-stage hardware, software and technology-enabled services firms. After his CEO experience, Peter served as an Operating Partner at Advent International, a leading global private equity firm managing $10 billion. Under Peter’s stewardship, several noteworthy firms were funded, grown and positioned for liquidity at premiums. Others were recognized among the Inc. 500 as fastest growing private companies. Several were brought to IPO. Some acquired and integrated with the acquired businesses, and/or were themselves acquired by industry leaders such as Computer Associates and Cisco Systems. As a result, Peter was recognized by Ernst & Young as an Entrepreneur of the Year finalist in New England. A decorated combat veteran, Peter served as an Army infantry officer in Special Operations in Vietnam. Through this life-altering experience, he developed a personal philosophy about the importance of surrounding himself with highly competent, well-trained and motivated individuals. It’s a philosophy he continues to lead his life by and one that he applies to his work every day at Safeguard. The opportunity to lead Safeguard appealed to Peter’s desire to apply both his strategic and deal-making experience to a forward-thinking company. His insights and lessons learned enable him to add value to Safeguard’s partner companies in areas where Safeguard can best apply its expertise, such as strategic planning, business development, sales, marketing, operations, mergers, acquisitions and finance. EXPERIENCE * Advent International – Operating Partner * Surebridge, Inc. – Chairman and CEO * Prime Response – CEO * Cayenne Software – CEO * Summa Four – CEO * On-Line Software International – President * Paramount Communications, Inc. (Software and Information Services Group) – President * Data General Corporation – Vice President & General Manager BOARD MEMBER Safeguard and Partner Companies * Clarient, Inc. (Nasdaq: CLRT) * Rubicor Medical, Inc. * Safeguard Scientifics, Inc. Independent Organizations * TechAmerica - Vice Chairman * National Foundation for Teaching Entrepreneurship (NFTE) – Advisory Board co-Chair EDUCATION * BA, University of Massachusetts at Amherst

As Senior Vice President and Chief Financial Officer, Steve leverages more than 25 years of strategic, financial and operational experience in raising capital and providing financial oversight, which greatly benefits Safeguard’s shareholders and partner companies. During the course of his career, Steve has demonstrated an ability to successfully grow and manage entrepreneurial enterprises. As Senior Vice President and Chief Financial Officer, Steve is responsible for all financial and administrative matters for Safeguard. He is also directly involved in providing oversight and support to Safeguard's partner companies, as well as participating in the development of Safeguard's long-term business strategy. Steve has the necessary public company skills that will ultimately drive value in Safeguard and its partner companies. Steve is responsible for analyzing and helping to identify the value-add that each partner company brings to Safeguard and its shareholders. Steve's experience complements Safeguard’s rich history and ensures a strong, disciplined financial infrastructure which drives excellence and accountability. Steve served as the interim Chief Financial Officer of Safeguard from December 2006 to June 2007. Prior to joining Safeguard, Steve held a number of financial and operating roles in both venture-backed and publicly traded companies. Today, in addition to his responsibilities at Safeguard, he is also the non-executive Chairman of the Penn Valley Group, a middle-market management advisory firm which launched in 2005. Prior to the creation of the Penn Valley Group, Steve served as the Chief Financial Officer of Fiberlink Communications Corp., a leading provider of remote access VPN solutions for large enterprises. Steve’s prior experience includes serving both as the Chief Financial Officer and then Chief Executive Officer of US Interactive, Inc. where he led the company’s initial and secondary public offerings. Steve also served as Chief Executive Officer of Concellera Software, Inc., orchestrating the sale of its proprietary technology to Hewlett Packard, and spent over a decade with Deloitte & Touche, where he was responsible for developing an emerging business practice for the firm in Philadelphia. The opportunity to rejoin Safeguard in June 2008 as its full time permanent Chief Financial Officer appealed to Steve’s desire to further apply his strategic, financial and operating skills to a broad array of companies. Steve has raised more than $200 million of growth capital through both venture sources and public offerings for a number of businesses. The application of these skills along with the financial oversight responsibilities of Safeguard serve to significantly leverage Steve’s substantial experiences for the benefit of Safeguard’s shareholders and partner companies. EXPERIENCE * Penn Valley Group – Founder and Managing Partner * Fiberlink Communications Corp – CFO * Concellera Software, Inc. – CEO * US Interactive, Inc. – CFO and CEO * Deloitte & Touche – Senior Manager BOARD MEMBER Safeguard and Partner Companies * Advantage Healthcare Solutions, Inc. * Clarient, Inc. (Nasdaq: CLRT) Independent Organizations * Arts & Business Council of Greater Philadelphia – Treasurer * Cadient, Inc. * Drexel University LeBow College of Business, Center for Corporate Governance Economics Pennsylvania – Regional Chairman * FMP Media, Inc. – Chairman * Internet Fitness, LLC * LaSalle University – Business Advisory Board * NutriSystem, Inc. (NASDAQ:NTRI) – Director and Chairman of Audit Committee EDUCATION * BS, LaSalle University